Longitudinal evolution of KSHV DNA copies in PBMCs, serum CRP, and peripheral blood CD19 B-cell counts in patients infected with HIV-1 with multicentric Castleman disease before and after treatment with 4 weekly infusions of rituximab. (A) Responders include patients 1 (i), 4 (ii), and 5 (iii) with complete remissions with no clinical symptoms with a follow-up of 3 to 12 months. (B) Nonresponders include patients 2 (i) and 3 (ii) without any response to rituximab. VL indicates viral load; D, day; W, week; and M, month. ▪ indicates CRP; ♦, CD19; and ▴, KSHV VL.